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Mitigating the risk of drug hypersensitivity reactions is an important facet of a given
pharmaceutical, with poor performance in this area of safety often leading to warnings,
restrictions and withdrawals. In the last 50 years, efforts to diagnose, manage, and
circumvent these obscure, iatrogenic diseases have resulted in the development of
assays at all stages of a drugs lifespan. Indeed, this begins with intelligent lead
compound selection/design to minimize the existence of deleterious chemical reactivity
through exclusion of ominous structural moieties. Preclinical studies then investigate how
compounds interact with biological systems, with emphasis placed on modeling
immunological/toxicological liabilities. During clinical use, competent and accurate
diagnoses are sought to effectively manage patients with such ailments, and
pharmacovigilance datasets can be used for stratification of patient populations in order
to optimise safety profiles. Herein, an overview of some of the in-vitro approaches to
predict intrinsic immunogenicity of drugs and diagnose culprit drugs in allergic patients
after exposure is detailed, with current perspectives and opportunities provided.
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Immune-mediated idiosyncratic adverse drug reactions constitute an existential threat to
prospective new chemical entities, encumbering the drug development process throughout its
progression in an abstruse fashion. Since these iatrogenic reactions are enigmatic and rare, they are
seldom encountered in the early stages of drug discovery, and often precipitate upon exposure to
wider populations with potentially terminal consequences for both patients and drug. It is therefore
astute to screen new therapeutics for the capacity to elicit such reactions, and attempt to eliminate
compounds with unacceptable liability for hypersensitivity early in development. Much investment
has been made to this end with several approaches developed, each with its advantages and
limitations. Non-human in-vivo models (1, 2) possess obvious limitations in terms of translational
relevance, and the fact that such equivalent models have been rendered obsolete in the field of
cosmetics safety perhaps indicates a finite time for their application in drug safety studies.
Despite continued efforts, understanding of hypersensitivity reactions is yet to reach satisfactory
resolution. It is therefore not surprising that preclinical screening does not yet provide a blanket barrierorg April 2021 | Volume 12 | Article 6305301
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these reactions. The central dogma of sensitization and elicitation
phases gleaned fromthefield of contact sensitization fundamentally
holds true for drug hypersensitivity reactions (3). Indeed, there is
consensus that the majority of these reactions proceed through the
basic dogmaofT-cell immunology; a T-cell receptor expressed on a
T-cell recognizing an antigen presented in the context of human
leukocyte antigen (HLA), with drug-induced perturbation of this
immunological synapse and the ensuing aberrant deployment of T-
cell responses a fundamental feature. Beyond this, the field
dramatically diverges, with multiple pathways of antigen
derivation gleaned to date; hapten (4), Pi (5), and altered self-
repertoire (6), outlined in (Figure 1) and reviewed in detail
elsewhere (7). Indeed antigen generation has been an important
focus of the field for some time, andwhile understanding is far from
complete in this area, there has been excellent progress, with some
studies elegantly demonstrating how antigens can be formed in
exquisite detail. Unfortunately, antigen generation is not itself the
critical determinant of hypersensitivity. Rather, it appears to be a
function of antigen perception and density. A simple, but helpful
way to consider the induction/precipitation of such reactions is
through a vaccine metaphor; broadly characterizing attributes into
antigenicity (signal 1) and adjuvant potency (signal 2), with a
plethora of drug and patient specific factors contributing to both
(Figure 2). Where hypersensitivity reactions are particularly
challenging is the immunological mechanisms that underpin the
initiating adjuvant sequence. This aspect, embodied as the “dangerFrontiers in Immunology | www.frontiersin.org 2hypothesis” (9, 10) is much less defined; it is heterogeneous, and
probably interchangeable, but essential for an antigen perception
that favours an aberrant T-cell response (11). It is known that signal
2 can be achieved via cellular stress/damage through damage
associated molecular pattern (DAMP) signaling, which can be
attributed to a drug by means of direct toxicological properties, or
throughdisease/environmental factors. It can alsobedeterminedby
pathogen associatedmolecular pattern (PAMP) signaling, as is seen
with infections. Finally, what has become clear in recent times with
the unpropitious outcomes seen with concomitant medication
usage alongside immune checkpoint inhibitors (12–17), is that
the adjuvant component is truly the dynamic and complex setting
of immune regulation, and that opposing tolerance mechanisms
play a critical role in determination of antigen perception.
Advanced discussion on the etiology of hypersensitivity reactions
is outside of the scope of this review; for extensive reading on this
topic, and themechanisms bywhichT-cells elicit cellular damage in
the context of drug hypersensitivity the authors refer readers to a
number of key reviews (7, 18–21).
These multi-mechanistic pathways of antigenicity and
adjuvanticity, overlaid with the variety of tissue specific factors
pertaining to localized metabolism, damage/pathogen derived
signaling and cellular milieu results in extensive heterogeneity of
these reactions. This heterogeneity makes preclinical assays with
good coverage challenging to construct. It also translates to the
challengeswithin the clinic in termsof clinical presentation. Indeed,
manifestations are diverse, and often lack pathognomonic featuresFIGURE 1 | Pathways of T-cell activation by compounds. Left to right; Hapten, pharmacological interact (Pi) and altered self-repertoire hypotheses for the
mechanism of antigen presentation in drug hypersensitivity. Adapted from (7, 8).April 2021 | Volume 12 | Article 630530
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methodologies challenging to obtain.
The imperfect classification of compounds yielded by
currently available preclinical assays has resulted in the
presence of many drugs with such issues within a physician’s
armamentarium. Therefore, effective and safe diagnosis of
hypersensitivity reactions when they do occur is paramount; in
order to mitigate the re-administration of offending agents and
identify liabilities of compounds in polypharmacy settings. As
direct re-exposure of hypersensitive individuals is undesirable
due to understandable patient anxiety and the potential for
extreme risk, it is transparent that there is demand for the
development of in-vitro methods in order to aid clinical
diagnoses of hypersensitive individuals whilst mitigating re-
exposure risk for suspected drugs. Hypothetically though, the
ultimate goal should be the development and implementation
of efficacious investigative procedures which facilitate
the circumvention of hypersensitivity in early product
development. Hence, this review predominantly covers the
topic of in-vitro diagnostic assays, and provides an overview of
the established and prospective efforts underway in preclinical
development to circumvent the progression of compounds
carrying unacceptable hypersensitivity risk profiles.Frontiers in Immunology | www.frontiersin.org 3IN-VIVO DIAGNOSIS/ASSESSMENT
Drug Provocation and Skin Testing
The gold standard for diagnosis of drug hypersensitivity is the
recurrenceof injuryuponrechallengewith theoffendingcompound
(24). Althoughnot infallible, positive re-challenges (often following
a positive de-challenge; where injury resolves upon drug cessation)
provide tangible and clinically relevant evidence for or against
hypersensitivity and thus whether continuation with the drug is a
viable course of action. A common feature of positive re-challenge
events is that the injury recrudesces in a more rapid and severe
manner (25). Although beneficial for the positive identification of
hypersensitivity, this phenomenon also represents a significant
drawback of re-challenge; the risk of serious injury or mortality.
This is highlighted by the 51% fatality rate reported for positive re-
challenge events concerning the general anaesthetic halothane (26).
As a result of this risk, many governing/advisory bodies issue
caution when considering re-challenge where drug-induced liver
injury or serious idiosyncratic adverse drug reactions are observed.
A common, less hazardous approach is that of skin testing;multiple
variations of skin testing exist,with the clinicallyutilised procedures
being the skinprick test, intradermal test, patch test andphotopatch
test. These assays have seen clinical validation and are usedApril 2021 | Volume 12 | Article 630530FIGURE 2 | Immunological perception of drugs expressed as a function of signal 1 x signal 2 factors, with an unknown composite (?) yielding hypersensitivity. Tol. =
tolerance, Act. = activation.
Hammond et al. Assays for Drug Hypersensitivityroutinely; for those seeking more comprehensive review of their
utility, the authors refer readers to several specialist publications
(27–34). Despite uptake within clinical practice, all 3 of the
described skin tests possess limited sensitivity and specificity, with
variable values for eachparameter reported in literature (28, 35, 36).
Given the limitations of skin testing, and the undesirable crux of
patient exposure to a compound they are suspected to be
hypersensitive to (37), there has been a longstanding necessity for
minimally invasive, in-vitro assays that add value in diagnosis of
compound hypersensitivity.
HLA Associations and Screening
The incredible capacity forHLAgenotype to predict an individual’s
propensity for hypersensitivity to a selectionof pharmaceuticals has
brought Pharmacogenetics to the fulcrum of discussion in the field.
The exquisite sensitivity of carriage of theHLA-B*57:01 “risk” allele
as a determinant of an individual’s susceptibility to hypersensitivity
with thenucleoside reverse transcriptase inhibitor abacavir (38–42),
is the quintessential utility of this approach. Indeed, not onlydid the
discovery of this association warrant the cost-effective and
efficacious implementation of preclusive screening of prospective
abacavir patients (43–46). It also laid foundations upon which
mechanistic studies were able to build, eventually leading to the
elucidation of a novel mechanism by which compounds can elicit
hypersensitivity (6, 47). HLA screening has also been adopted for
circumvention of SJS/TEN hypersensitivity reactions associated
with carbamazepine, with HLA-B*15:02 featuring as the
implicated allele (48). Application of pharmacogenetics is now a
widespread method by which information on hypersensitivity
reactions with given compounds is divulged, with a brief
investigation of literature yielding no shortage of manuscripts
sporting comprehensive lists of such associations. While the
aforementioned HLA alleles, among others, possess exploitable
odds ratios, many of the cited associations are not of consequence
in terms of viable/cost effective mitigating action. The
reproducibility of studies utilizing this approach has also been
questionable on a number of occasions. Inversely, the fact that
positive predictive values even in the most impressive of allelic
associations are not 100% [abacavir exhibits only around 55% PPV
(40)], alludes to the notion that confounding factors further
influence susceptibility. Thus, while HLA alleles occasionally
constitute a critical prerequisite, they far from guarantee the
manifestation of hypersensitivity reactions (8).
Another, more fundamental issue with HLA screening in
prediction of hypersensitivity is the paradoxical juxtaposition
between prediction and retrospection of this approach. Crucially,
a prerequisite to the delineation of risk alleles is the exposure of
(often immensely proportioned) patient populations to a given
pharmaceutical. Thus, patient safety is breached at the inception of
these studies (an undesirable outcome in any case), therefore, HLA
screening is currently confined to being a tool generated from
clinicaldata,whichonoccasionhasproven topowerfully contribute
to the iterative process of optimization of drug safety profiles.
Nevertheless, elements of this can, and have been incorporated
into preclinical prospective platforms, some of which are
covered below.Frontiers in Immunology | www.frontiersin.org 4IN-VITRO DIAGNOSTIC/INVESTIGATIVE
ASSAYS
LTT
The lymphocyte transformation test (LTT) has been a mainstay
in the limited toolkit for in vitro diagnosis of hypersensititivity
for around half a century, with several technical revisions since
its inception (49–52). An LTT entails the culture of PBMC from
an individual with suspect compounds for 6-7 days, with the
output being a function of lymphoblastic transformation/
proliferation. Several variations have evolved since the primitive
methods described by Halpern & Amache, 1967 (53), each with
benefits and drawbacks. The most prominent of these is tritiated
3H-thymidine incorporation (Figure 3). Less hazardous options
include ELISA-based 5-bromo-2’-deoxyuridine incorporation
method, or carboxyflourescein diacetate succinimidyl ester
(CFSE) serial dilution and ki-67 expression as measured by flow
cytometry. CFSE/dye dilution-type and ki-67 based assays have an
additional advantage in that they can facilitate identification of the
effector cell of origin (54). However both come with concerns over
technical requirements, and ease of interpretation.
LTT results appear to be highly variable in terms of sensitivity
and specificity, with concerns over sensitivity in particular
drawing criticism which dates back to its early use (55).
Confounding factors include; the clinical manifestation of the
reaction (and thus the presentation-specific mechanisms),
latency from reaction to test, the culprit compound in question
[whether it possesses properties intrinsically inhibitory or
stimulatory to T-cell proliferation e.g.; methotrexate (56)],
concomitant therapy that may have bearing on the test such as
immunosuppressant therapeutics, and (often overlooked)
laboratory specific technique.
Clinical manifestations of drug hypersensitivity are, as
discussed (8, 22, 53) heterogeneous. This heterogeneity and the
delay from reaction to LTT has been posited to be absolutely
critical to the validity of the test. Conventionally, a minimal
interval of 3 weeks is allowed to elapse before in vitro tests begin,
a l l ow ing e l im ina t i on o f bo th cu lp r i t d rug s and
immunosuppressant/anti-allergic drugs (57). Presumably this
period also correlates with contraction of the adaptive response
and the development of a memory component that is stabilized
in terms of proliferation (as in the acute phase, highly activated
PBMC may generate backgrounds which conceal responses).
Further complicating this area is the contrasting time-LTT
response relationship seen depending on the manifestation of
the hypersensitivity reaction. Findings by Kano et al. (58),
indicate that allowing time to elapse following hypersensitivity
leads to opposite effects in merit of the test depending on the
clinical presentation; patients with SJS/TEN exhibited prominent
LTT responses in the acute phase (within 1 week), which
substantially diminished upon recovery phase (>5 weeks),
whilst the inverse was seen in DIHS/DRESS patients.
The transparency of compound specific variation of LTTs is
epitomized by the fact that stimulation index (SI) values (and
thus threshold of the definition of positive responses) are not
universal. Rather, they are determined through experience withApril 2021 | Volume 12 | Article 630530
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assigned a threshold SI of >2, Beta lactams tend to be assigned a
threshold of >3, and some radio contrast media responses must
reach SIs >4 to be deemed positive (57). With this comes several
issues which the field has failed to address universally, the first of
which being inconsistent threshold SI values utilized throughout
literature for compounds. For example; SIs of >2 (59), >3 (60)
and >4 (57) have been adjudicated as positive responses for radio
contrast media. Similarly, there remains inconsistency with Beta
lactams, with SI thresholds set at >2 (61), and >3 (57). In light of
this, one may be tempted to speculate that the stimulation index
(and thus sensitivity and specificity of lymphocyte
transformation test) is “optimized” to the data it generates.
Therefore, when interpreting the sensitivity and specificity of
the test cited throughout literature, this must be considered as aFrontiers in Immunology | www.frontiersin.org 5potential caveat. To optimize diagnosis of hypersensitivity, it
would be of best interest to the field to universally agree on pre-
defined SI thresholds, retrospective analyses of cumulative data
from multiple laboratories may be a fruitful avenue in this
respect. A second, seemingly less rectifiable issue, is that if SI
threshold values may only be set retrospectively, the LTT
(although useful as a diagnostic tool for hypersensitive
individuals), is inherently flawed for use in determining/
diagnosing potential immunogenicity of a prospective
therapeutic compound in early clinical development.
Concomitant therapy is common in the aftermath of drug
hypersensitivity reactions, not least due to medication taken to
alleviate the reaction itself. The nature of these drugs has been
suggested to influence the results of LTTs, immunosuppressant
drugs such as corticosteroids (e.g.: prednisolone) have beenFIGURE 3 | Overview of lymphocyte transformation test methodology.April 2021 | Volume 12 | Article 630530
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responses, patients taking > 0.2 mg/kg of such drugs are often
excluded (62). Prostaglandin E2 concentration has also been
posited to influence LTT results with high levels (as seen with
macrophage overrepresentation in culture) and low levels
(sometimes caused by use of non-steroidal anti-inflammatory
drugs) reducing and enhancing LTT responses respectively (63).
Attempts to revise the LTT have included enrichment of
professional antigen presenting cells within the culture, inclusion
of metabolites derived from parent drug, depletion of T
regulatory populations, and effector cell identification/
evaluation. The enrichment of immature dendritic cells (CD14
+ve) and independent pulsing with antigen prior to co-culture,
demonstrated superior LTT responses in patients with
amoxicillin induced maculopapular exanthema relative to
standard B cells and monocytes. These modifications enhanced
sensitivity, while tolerant controls remained negative- thereby
maintaining specificity (64). Concordant results were also
obtained from patients with heparin hypersensitivity, with the
added advantage of prolongation of the sensitive detection
period following the ADR (65). Antunez et al. investigated
maculopapular exanthema reactions induced by iodine contrast
media, finding that the CD14 enriched LTT yielded superior
responses in most (but not all) patients (60), with the enrichment
attenuating one patients response, and raising the baseline
proliferation in at least one control. Prevailing thoughts
regarding the mechanisms underpinning the superiority of
dendritic cells as antigen-presenting cells (APC) in LTTs
include that they are simply more adept at antigen
presentation, or that as observed with nickel and DNCB (66)
compounds can induce their maturation directly, in a manner
that promotes immunological elicitation. The subtype of
dendritic cells used to enrich the LTT must also be given
consideration, as heterogeneity in response to nickel was
detected when comparing Langerhans cells and circulating
dendritic cells.
The role of regulatory T cells has also been scrutinized in recent
times, with selective depletion of these cells from LTTs being
attempted in several assays. One premise being that in some cases,
although drug-specific precursors may exist, their response is
suppressed by the action of regulatory T cells, hence, in their
absence, the sensitivity to compounds would be unveiled. To this
end, CD25+ve depletion from the culture has been utilized several
times, as regulatory T cells constitutively express high levels (67,
68). In the context of allergic contact dermatitis (69), CD25 +ve
depletion encouragingly yielded augmented responses to the
contact allergens 2,4,6-trinitrobenzene sulfonic acid, FITC, and
a-hexylcinnamaldehyde. However, responses to non-sensitizing
compounds such as dimethyl sulfoxide were also augmented
(albeit generally to a lesser degree). Additionally, CD25 is not
exclusively highly expressed on regulatory T cells, and it is well
documented that it is also expressed on B cells, activated effector T
cells and certain subsets of memory T cells (68, 70–72). Therefore,
the depletion of CD25 expressing cells may have unprecedented
effects on the utility of the LTT (especially if PBMC are sampled in
the acute phase as recommended in SJS), due to collateral removalFrontiers in Immunology | www.frontiersin.org 6of these other cell types, potentially resulting in false negative
results through removal of drug-activated T-cells, rather than the
unveiling of an otherwise suppressed response. Another
modification pertaining to immune-regulation is the
incorporation of immune checkpoint inhibitors. Sugita et al.
(73) reported that incorporation of CTLA-4 augmented LTT
sensitivity. This is an enticing prospect, but a critical question to
address here would be the extent to which the enhanced sensitivity
observed impacts upon the specificity of the assay. Regulatory T-
cell components and regulatory pathways are likely to be critical in
determining the hypersensitive status of individuals, and so false
positive results would be a possible eventuality with their removal/
suppression. A more detailed understanding of utility of such
approaches within LTTs (perhaps even considering inter-
individual components) is therefore required before it will be
appropriate to routinely apply checkpoint inhibitors within
such assays.
The inadequacy of the LTT in addressing metabolites derived
from the parent drug may contribute to its lack of sensitivity, as
some metabolites may be tissue specific. Indeed, the erratic
returns from LTTs performed on drug-induced liver injury
patients serve as testament to such limitations (74), as does the
enhanced diagnostic performance of this assay when relevant
drug metabolites are synthesized and included in LTT
assessment of compounds known to undergo bio-activation
(75). For metabolite coverage, several variations on LTTs have
been utilized, but often these models are cumbersome;
commonly relying on allogeneic metabolizing systems/cell lines
such as rat/human hepatic microsomes, hepG2, hepaRG cell
lines or primary hepatocytes to generate reactive metabolites,
therefore restricting direct cellular contact and/or coming with
the distinct caveat that allogeneic responses may undermine the
assay. Nevertheless, some success has been reported with such
approaches, though a degree of allogeneic response is duly
reported (76, 77). In a research setting, the ultimate goal to
overcome such issues would be to incorporate autologous tissues
such as keratinocytes or hepatocytes which could possibly be
derived through induced pluripotent stem cells, though this is
impracticable for routine diagnostics. A utilitarian solution to
installment of metabolizing systems within the LTT should be
pursued if this assay is to realize its maximal potential in terms of
diagnostic value for reactions attributable to metabolites.
Since PBMCs are the cellular input into the LTT,
consideration must always be given that the output will reflect
this. While use of these circulating lymphocytes is minimally
invasive and is relatively practical, it does ultimately mean that
translational relevance of any LTT outcome is a function of
responses arising from circulating populations of lymphocytes.
This equates to surveying only a small percentage of peripheral
blood T-cells, which, even in totality, actually only represent
around 2-2.5% of the entire T-cell complement populating an
individual (78). Thus, tissue resident T-cells and specialized
antigen presenting cells will be poorly (if at all) represented,
and it remains imperative to consider this limitation when
assessing hypersensitive statuses of patients exhibiting tissue
specific responses. A similar argument may also be made forApril 2021 | Volume 12 | Article 630530
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repertoires. Moreover, LTTs are somewhat limited in
sensitivity even if the relevant cells are present within samples.
Indeed, signals from T-cells present at only low pre-cursor
frequencies can be lost among backgrounds generated by
heterogeneous populations within PBMCs, as has been
demonstrated through T-cell cloning procedures conducted on
bulk cultures from patients negative in LTTs (79–81). This is a
limitation of bulk proliferation assays and indicates that there is
room for improvement in terms of the threshold at which
presence of T-cells actually yields detectable responses in LTTs.
Finally, the quality of PBMCs available for such assays has
substantial bearing on the validity of the assay; the idealistic
scenario is that PBMC isolation and LTT can be performed on
fresh blood within hours of phlebotomy. Frozen PBMC is
reputed to be less reliable, which may be attributable to
differential sensitivity to cryopreservation across cellular
components (82), particularly if this significantly alters the
composition of the resulting PBMC. Regardless, robust LTT
responses have been observed in patient samples that have
been isolated and cryopreserved, and shipped internationally to
specialist laboratories. Thus, if PBMC are proficiently isolated
and cryopreserved, this may represent a more pragmatic option.
Another potential avenue of consideration for the LTT is that
entire formulations must be scrutinized- a recently well
documented example has been that of clavulanate, which is co-
formulated with amoxicillin and ticarcillin to augment
antimicrobial efficacy by functioning as “cannon fodder” for
bacterial beta-lactamase enzymes, acting as a substrate and thus
competitively inhibiting the lactamase action on the primary
active ingredient. Unfortunately however, the addition of
clavulanic acid to amoxicillin precipitates drug-induced liver
injury in a percentage of patients which is not eclipsed with
amoxicillin alone (83). Later studies depicted distinct
immunogenicity profiles for both compounds, with no cross
reactivity, indicating the immunogenicity of clavulanic acid (84).
Further expanding investigation of formulation leads to inclusion
of excipients for a given therapeutic. Indeed, when pure
substance is not available, it is recommended that injectable
forms of the drug or crushed pills are used (62), albeit with the
caveat of procedural artifacts. On the flipside to this however, is
that batch specific immune reactions due to impurities/
contamination could perhaps be identified through tablet
testing, potentially absolving an active pharmaceutical
ingredient of responsibility for a reaction. It is feasible that
investigations of this nature could be facilitated by stability
samples stored by pharma.
Cytokine Synthesis and Secretion
Detection Assays
In-vitro tests targeting the function of the drug specific T-cells;
cytokine/cytolytic molecule secretion assays can be both
diagnostic of an individual’s hypersensitivity status, and
informative in relation to pathomechanistic aspects of the
reaction (85). Typical procedures used include ELISA, ELISpot
(Figure 4), flow cytometry (intracellular cytokine staining), PCR
and cytokine bead array assays. The detection parameters in suchFrontiers in Immunology | www.frontiersin.org 7assays ultimately correspond to the synthesis and/or secretion of
a given cytokine, which raises the predicament of which
cytokines to use. Cytokines including IFN-g, IL-2, IL-5, IL-13
and various cytolytic molecules such as perforin, granzyme B,
and granulysin often feature, each with its merits and
disadvantages depending on the clinical presentation and
compound in question (57). This lead to the general
recommendation that a panel of cytokines be used in order to
enhance the highly variable sensitivity reported (86). Advantages
of cytokine assays include the mechanistic insight provided and
the relatively quick time to result (3 days), while drawbacks are
the reported lack of specificity, high expense and specialist
technical requirements.
Surface Marker Expression Assays
Cluster of differentiation 69 is a member of the c-type lectin
family involved in T-cell proliferation pathways (87). The
upregulation of this marker (measured using flow cytometry)
has therefore been utilized as an early activation marker of T-
cells in delayed drug hypersensitivity and has been compared to
the LTT with advantages being the quicker time to result (48 hrs
rather than 1 week), the omission of the use of radioactive
materials and some drug-specific peculiarities (88, 89). Markers
associated with T-cell cytotoxic effector functions have also been
interrogated for use in causality assessment. Intracellular
granulysin expression in NKp46+ve and CD4+ve cells has
been proposed in the problematic assessment of SJS/TEN (90).
Similarly, surface expression of the degranulation CD107a
(LAMP1) on T and NK cells, has been described for
heterogeneous hypersensitivity reactions, and provides
comparable mechanistic insight to that provided by ELISpot/
ELISA assays (91). Other activation induced surface markers
such as CD154, CD25, OX40 and PDL-1 have been used in
vaccine development for some time (92, 93), notably for the
detection of rare memory T-cell responses (94). Approaches such
as these may therefore be of interest as sensitivity of many
aforementioned assays is inadequate.
Cytotoxicity
Inter-individual differences in the toxicological profiles of
compounds (essentially detected in non-specific toxicity assays)
have been linked to the hypersensitivity status of patients in
several different settings. Early studies identified augmented
cytotoxicity in hypersensitive patient PBMCs when co-cultured
with metabolism conferring murine microsomal activating
systems (95–97). Despite obvious caveats with these assays;
namely the use of a xenoco-culture system, the observation of
such toxicity appears to constitute a link between direct toxicity
intrinsic to the individual, and the ensuing immunogenicity seen
in immune-mediated idiosyncratic adverse drug reactions.
Interestingly, the discrepancy in sensitivity exhibited hereditary
correlation as parents of hypersensitive individuals expressed
intermediate sensitivity (between controls and patients) (95),
indicating a discernible role of intrinsic genetic predisposition
factors. Several decades later, this approach was reinvented,
employing the use of monocyte derived hepatocyte-like cells to
form an autologous, metabolically competent model (98).April 2021 | Volume 12 | Article 630530
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toxicity in monocyte derived hepatocyte-like cells was useful in
causality assessment of idiosyncratic drug induced liver injury
with comparable accuracy to that of the “gold standard” Roussel
Uclaf causality assessment method (99, 100). Although this
avenue of hypersensitivity investigation is in its early stages of
resurrection, with other groups yet to replicate findings of these
studies, it holds much promise both in utility as a diagnostic/
predictive tool, and as a probe for understanding of the
fundamental pre-disposing factors that influence an
individual’s propensity for hypersensitivity.
Perspective of Diagnostic Assays
To summarize, a number of diagnostic options can be pursued
by a clinician in order to seek confirmation that a pharmaceutical
agent should be contraindicated on the grounds ofFrontiers in Immunology | www.frontiersin.org 8hypersensitivity. A conceptual shift has been underway for
some time toward these tests being conducted ex-vivo, with the
aim of obtaining diagnostic information while eliminating the
risk of exposure for the individual in question. Unfortunately
however, the battery of available in-vitro assays are still at various
stages of development and are not yet of adequate maturity
(through respective sensitivity/specificity/accessibility/
standardization) to be routinely implemented into algorithms
currently deployed for clinical diagnoses. It is disappointing that
no functional diagnostic assay has achieved validation to date,
especially given the length of time some have been studied for. A
prime example of this is the LTT, which for nearly half a century
has probably been the most established and clinically recognized
in-vitro diagnostic assay, and therefore best situated for clinical
validation. This is attributable to its unreliable sensitivity/
specificity , and perhaps more importantly , lack ofFIGURE 4 | Overview of enzyme-linked immunospot (ELISpot) assay.April 2021 | Volume 12 | Article 630530
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cumbersome in-vitro technologies routinely used, this assay is
not likely to see clinical implementation within the next decade.
The widespread availability of flow cytometry probably means
that any easily implementable assay will arise on this platform.
Such an application also provides opportunity to multiplex
features of several of the aforementioned parameters, with this
type of approach likely to yield a superior, or at least more
utilitarian assay. In order to facilitate this, research groups
equipped to conduct these assays will need to harmonise
protocols and readout thresholds in order to work
collaboratively in the establishment of what would be the first
legitimized in-vitro option for diagnosis of hypersensitivity
reactions. Thereafter, efforts can be directed toward the
enhancement of its sensitivity and specificity with several
promising avenues discussed. As adeptly demonstrated
through the peculiar retrospective/predictive properties of HLA
genotyping, translational solutions are long-awaited and can be
exceptionally effective in this area, but it takes standardized,
translational approaches to deliver them.
As aforementioned, an idealistic goal would be to minimize or
render obsolete the diagnostic field through the installation of
effective preclinical screening assays. This is far from realization,
with several compounds reaching clinical phases of development
before programme termination in recent times, and numerous
drugs in clinical circulation that have less than desirable records
in terms of hypersensitivity rates. There has therefore been no
shortage of incentive to gauge the intrinsic immunogenicity of
prospective pharmaceuticals within preclinical development in
order to select optimal lead compounds for progression. The
remainder of this review therefore focuses on some of the
established strategies employed within industrial settings, and
outlines novel assays currently in development that may one day
form part of preclinical safety studies.PROSPECTIVE ASSESSMENT
OF IMMUNOGENICITY
Structural Alerts
Around 30 years ago, John Ashby, of imperial chemical
industries, identified a codification of chemical structures that
possessed genotoxic liabilities; structural alerts (101, 102). This
codification was largely constructed from empirical evidence
accumulated on chemical moieties responsible for covalent
binding to cellular macromolecules (103–108). Since then, this
basic dogma of identifying electrophilic structures that react with
biological nucleophiles has undergone iterations and refinements
for a variety of toxicological applications. Indeed, several in-silico
models are now available for use as rapid, cheap, guidance tools
for prediction of chemical toxicity, with the benefit of application
before a compound is even synthesized (109). Understanding of
the fundamental mechanisms of electrophilic reaction chemistry
is therefore important in order to facilitate this philosophical
shift from empirical knowledge, toward more general rules
which can help inform design of such predictive tools. On thisFrontiers in Immunology | www.frontiersin.org 9note, electrophilic reactions with biological nucleophiles have
been posited to proceed through 6 basic mechanisms; SN1, SN2,
SNAr, acylation, Michael addition and Schiff base formation
(110). For each of these, the outline of mechanism, alongside a
pertinent example is provided in (Figures 5 and 6).
Though compounds can be intrinsically reactive as seen with b-
lactamantibiotics (121), the true extent of conjugative chemistry for
a given compound is often a function of its capacity to form reactive
metabolites. Hence, the term toxicophore can be used
interchangeably with structural alert, to refer to a compound
which has reactivity imparted via metabolism. This has been
identified as a mechanism of direct toxicity (122–124), with a
direct link to hapten theory, and the propensity of compounds to
cause idiosyncratic, immune-mediated reactions (125–127). The
ratio of the appearance of structural alerts across drugs withdrawn/
issued a black box warning relative to drugs with superior safety
profiles demonstrates their unpropitious nature (128). Examples of
chemical moieties that commonly feature in drugs that cause
idiosyncratic toxicity include p-aminophenols or aromatic amines
that can be oxidized to them (quinone reactive metabolites) (128–
130), and anilines/anilides (hydroxylamine/nitroso reactive
metabolites) (131–133). The logical application of such findings is
therefore to design out structural alerts either in early compound
design, or in an iterative fashion once the initial compound
encounters idiosyncratic safety issues. One straightforward
example to illustrate this approach can be found with the non-
steroidal anti-inflammatorydrugs suprofenandketoprofen(Figure
7, top). Suprofen, which contains a thiophene structural alert, was
withdrawn due to renal toxicity (134–136). Toxicological salvation
can be achieved via replacement of the thiophenemoiety present in
suprofen with a phenyl ring, resulting in the safer alternative
ketoprofen (137). Another example can be found in the evolution
of antimalarial 4-aminoquinolones. Clinical utility of amodiaquine
has been somewhat vitiated by its capacity to elicit idiosyncratic
adverse drug reactions; particularly hepatotoxicity and
agranulocytosis (138, 139). Amodiaquine sports an aminophenol
structural alert which undergoes enzyme-mediated oxidation to
form a reactive quinoneimine species which covalently binds
proteins and elicits immunological responses (129, 140–145). To
circumvent this deleterious bioactivation, several routes of
structural redesign were pursued (Figure 7, bottom); including
the addition of two electron accepting groups at 3′ and 5′ positions
to enhance potency (146) and isomerization of the 4′-hydroxyl
group with the 3′-diethylamino side chain or fluorination of the 4′-
position to prevent quinonoid bioactivation (147, 148).
Structural alerts represent an anecdotal weight of knowledge
through experience and should therefore be used accordingly; as
a guide rather than a standard operating procedure. They far
from guarantee safety; even if one was to eschew from all leads
containing structural alerts, there exists several high profile
examples of drugs lacking such motifs that have been
withdrawn due to idiosyncratic toxicity (ximelegatran,
chlormezanone, isoxicam, and pemoline) (128, 149, 150).
Conversely, hit attrition concerns highlight how unsatisfactory
such a parochial approach would be, with toxicophores
frequently featuring in top pharmaceuticals (128, 151), andApril 2021 | Volume 12 | Article 630530
Hammond et al. Assays for Drug HypersensitivityFIGURE 5 | Mechanisms of covalent binding. Outline of the 6 key mechanisms by which electrophiles react with biological nucleophiles with an example compound
provided for each. SN1; Tamoxifen O-sulfonate metabolite (derived from sulfonation of a-hydroxytamoxifen) can collapse yielding an allylic carbocation reactive
metabolite susceptible to nucleophilic attack, resulting in protein and adducts (111–114). SN2; Carbamazepine (CBZ) 10, 11 - epoxide (reactive metabolites derived
from carbamazepine) (115). SNAr; Dinitrochlorobenzene (116).Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 63053010
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149, 151). Furthermore, while structural alerts indicate the
possibility of a molecule covalently binding, this does not
always translate; compounds containing structural alerts do
not always form chemically reactive metabolites, and
competing clearance pathways can trivialize the presence ofFrontiers in Immunology | www.frontiersin.org 11alerts that do undergo bioactivation (128, 149). With regards
to hypersensitivity, these examples serve to demonstrate that
avoidance of structural alerts is not essential, that total body
burden of chemically reactive metabolites (and therefore ensuing
antigenic density) can be an important determinant, and that
subtle re-design can save a lead compound.FIGURE 6 | Mechanisms of covalent binding. Outline of the 6 key mechanisms by which electrophiles react with biological nucleophiles with an example compound
provided for each (continued). Acylation; B-lactam containing compounds (117). Michael addition; N-acetyl-p-benzo-quinone imine (NAPQI) (reactive metabolite
derived from Paracetamol) (118). Schiff base formation; glyoxal (released via bioactivation of sudoxicam) (119, 120).April 2021 | Volume 12 | Article 630530
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structural alerts, this type of approach currently only has utility for
drugs which exert antigenicity via hapten/covalent binding related
mechanisms. However, as patterns of drug hypersensitivity via the
various mechanisms continue to emerge, perhaps we will
eventually see inclusion of chemical codifications which confer
immunogenicity, through each or all of the described antigenicity
mechanisms [Figure 1, (8)], and/or particularly high affinity
interactions for (common) constituents of the immunological
synapse. One can envision that a nascent database of such
“Immunocophores” could be procured from compounds that
have failed at various stages of development due to idiosyncratic,
immune-mediated toxicity and used to mitigate risk. Proof-of-Frontiers in Immunology | www.frontiersin.org 12concept iterative medicinal chemistry studies in pursuit of an
analogue of abacavir devoid of hypersensitivity liabilities with
preserved pharmacological action have embodied a promising
prototypical approach to disconnect pharma- and immuno-
cophores. Cross-disciplinary laboratories operated using in-silico
docking models alongside functional studies to simultaneously
decipher pharmacological (anti-viral) and immunological (T-cell
activation) structure-activity-relationships of compound series
(152, 153). Digressing from such idealistic goals, many of the
following experimental assays have essentially been devised to
address various aspects that lie within the void of knowledge
between such conventional theoretical chemistry-based wisdom,
and pragmatic transition of a compound to clinical use.FIGURE 7 | Pharmaceutical application of structural alert chemistry. Top panel; Disparity in metabolic fates of suprofen and related ketoprofen, and their
downstream tolerability profiles, are generally attributed to suprofen’s possession of the thiophene ring structural alert which is capable of undergoing oxidation to
S-oxides/epoxides. Ketoprofen’s phenyl ring does not undergo equivalent bio-activation. Middle panel: Iterative synthesis series of amodiaquine in pursuit of a
compound with reduced ADR liabilities; Amodiaquine possesses the p-aminophenol structural alert which can be bioactivated to the Michael acceptor ACQI which is
reported to be responsible for its idiosyncratic ADR liabilities in a fashion akin to paracetamol and NAPQI. Structural analogues in the form of fluorination at the 4
positions, or isomerization of the hydroxyl and diethylamino side chain leads to compounds impervious to quininoid bioactivation.April 2021 | Volume 12 | Article 630530
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Reactive electrophile species formed through the bioactivation of
drug candidates often exhibit insufficient stability to be directly
identified through liquid chromatography-mass spectrometric
methods. Hence, in order to delineate metabolites that can be
derived from a given compound, a metabolically competent in-
vitro system (cofactor fortified S9 fraction, microsomes,
hepatocytes) is employed to generate reactive metabolites, which
form adducts with characterised endogenous or exogenous
nucleophiles, yielding “smoking gun” conjugates, providing
insight into reactive metabolites formed and the mechanism by
which they interact with nucleophiles (Figure 8). Since
endogenous nucleophiles do not lend themselves to high
throughput screening methods, in early compound
development, small molecule nucleophilic traps are preferred.
The armamentarium of these nucleophilic warheads includes the
thiol-containing soft nucleophiles (glutathione, cysteine, N-
acetylcysteine and 2-mercaptoethanol) for detection of soft
electrophiles, and non-thiol hard nucleophiles (cyanide,
semicarbazide, methoxylamine, DNA bases) for detection of
hard electrophiles (154). These types of assays are mostly
qualitative, but a degree of quantitative value can be added
through the incorporation of radiolabelled analogues of
corresponding nucleophile probes [35S] GSH and [14C]
KCN (155).
Electrophile trapping assays are amenable to high throughput
screening translation/automation and so feature prominently
across drug discovery programmes. Despite their value and
widespread utility, limitations to application of trapping in
hypersensitivity prediction include: 1. the nucleophiles
themselves, as any approach using exogenous nucleophiles is
reliant on the assumption that these selected surrogate
nucleophiles recapitulate the mechanism of adduct formation
on biological macromolecules in a toxicological ly/
immunologically relevant fashion. 2. The physiological
relevance of the somewhat simplistic in-vitro cultures (as
detoxification pathways are not well accounted for). 3. Reactive
compounds missed by such assays such as acyl glucuronides and
CoA thioesters (154).
Adductomics
Adductomics denotes a method that studies the magnitude of
covalent adducts bound to tissue or blood nucleophiles which
can characterise the electrophilic potential of drugs or indeed
their bioactivated metabolites. This procedure involves the co-
incubation of the drug-metabolite in question with conjugate
proteins such as GSTP or HSA in a dose dependent manner
(115). The formation of adducts can then be quantified by the use
of western blotting or mass spectrometry to identify the bound
amino acid residue. Protein adduction studies have been pivotal
in the research of a plethora of drugs/metabolites to delineate the
mechanism by which they elicit T-cell activation and whether the
parent drug or a metabolite thereof exhibits the immunogenic
liability (156). Jenkins et al. successfully identified the irreversible
binding of flucloxacillin to HSA, in a mechanism involving
nucleophilic attack of the b-lactam ring of flucloxacillin toFrontiers in Immunology | www.frontiersin.org 13lysine residues present on peptides (157) (Figure 6). This
procedure has also been used for mechanistic resolution in
discrimination between drugs which possess hapten
functionalities and those which do not. One rather
controversial example in this light is the antibiotic
sulfamethoxazole, which is known to activate T-cells through a
mechanism which bypasses antigen processing, namely the PI
mechanism (5, 158–160) (161). However, sulfamethoxazole
undergoes oxidative bioactivation to yield the metabolite
nitrososulfamethoxazole. This metabolite exhibits strong
reactivity toward cysteine residues, forming covalent bonds
and acting as a hapten (131, 162). Accordingly, distinct
patterns of T-cell activation between the relatively inert parent
drug and a bioactivated metabolite can often be obtained from
mechanistic studies on isolated T-cell clones (158).
Despite protein adduction of a compound not converting to a
compounds liabilities in terms of capacity to elicit
hypersensitivity reactions in a straightforward fashion. Drug-
protein adducts have been successfully identified with antibiotics
such as piperacillin (163), flucloxacillin and amoxicillin (164,
165) as well as reverse transcriptase inhibitors such as nevirapine
(166). This approach has also been utilised to identify a range of
peptides susceptible to covalent modification by the drug/hapten
in question (121). Successful identification of such a drug-
modified protein can then allow for the synthesis of designer
peptides which can be integrated into T-cell assays, for analysis
of their immunogenic potential (167), in a similar manner to
those designed for vaccine use (168). An area of interest which
may be important for the future of adductomics (with regards
to both investigative and preclinical assays) will be the
selected endogenous nucleophiles, and whether there may be
some proteins for which covalent binding is poorly
immunologically tolerated.
Peptide Elution Studies
Within the human system HLA complexes are essential proteins
which are expressed on the surfaces of many cell types which
function to present peptides to T-cells. MHC class I, which
presents to CD8+ T-cells, is comprised of HLA-A,B and C
molecules. Meanwhile, HLA class II serves to present to CD4+
T-cells, and consists of HLA-DP, DQ and DR molecules. Many
peptides from the constitutive repertoire of the host are tolerated
by T-cells due to prior exposure during thymic development.
However, peptides encountered thereafter such as those of viral
or bacterial origin can elicit an immune response if accompanied
by appropriate co-signaling and the presence of DAMPs or
PAMPs (169).
Several approaches can be utilised to isolate HLA-bound
peptides from a variety of cell lines. The simplest of which
entails acid stripping the surfaces of cells in culture using an
acidic buffer (170–172). However, this has been reported to result
in high levels of contaminating peptides which can hinder the
analysis of the immunopeptidome. A more commonly utilised
approach involves the direct separation of solubilised HLA-
complexes isolated from cell lines. This approach entails the
immunoprecipitation of HLA molecules and the subsequentApril 2021 | Volume 12 | Article 630530
Hammond et al. Assays for Drug Hypersensitivitydissociation of the HLA-bound peptide complex which can then
be analysed via m/s [Figure 9, (173, 174)].
Mass spectrometric analysis of HLA-peptide complexes has
successfully identified thousands of natural MHC peptides
presented on the cellular surface. These studies have been
successful in the identification of the peptide binding
preferences to alleles in a plethora of diseases including type
1 diabetes (175) and cancer (176, 177). Peptide elution studiesFrontiers in Immunology | www.frontiersin.org 14have also been carried out as a pre-requisite for the study
of peptide binding HLA’s, and in such cases helped to identify
the N-terminal escape of 9-11 mer peptides when HLA
bound (178).
It is well known that the induction of hypersensitivity
reaction entails the presentation of a drug-related antigen on
the surface of MHCs for scrutiny by T-cells. Indeed, this has been
an area of considerable interest in recent times, including theFIGURE 8 | Overview of electrophilic trapping workflow.April 2021 | Volume 12 | Article 630530
FIGURE 9 | Procedural workflow of peptide elution assays. MHC complexes are purified from the samples, which can comprise of cultured cells (i.e. transfected
B-cells expressing HLA allele of interest), or cells deriving from whole organs or biopsies (liver). Cell pellets can be ground using cryogenic mill and are then lysed.
Immunoprecipitation takes place from the cell lysate, this occurs through running the sample through columns specific for the MHC in question, as well as a pre-
column to remove non-specific binding. HPLC is then conducted to separate the MHC peptides from the larger components such as b2M and the alpha chain.
Pooled fractions can then be analyzed via m/s allowing for the identification of modified peptides or an altered repertoire of peptides presented to T-cells.
Hammond et al. Assays for Drug Hypersensitivity
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of peptides on the surface of MHC. Elegant studies conducted by
Illing et al. in 2012 utilised peptide elutions to positively identify
a skewage toward peptides terminating in small aliphatic amino
acids (I, L and V) over the conventional aromatic amino acids
(F/W/P) in HLA-B*57:01+ APCs co-incubated with abacavir
(179). This was achieved via the prolonged incubation of C1R-
B*57:01 cells with abacavir followed by peptide elutions from
the class I MHC and analysis by mass spectrometry (m/s). This
was further reinforced in 2019 when abacavir analogues with a
similar T-cell liability were found to perturb the HLA-B*57:01
peptide repertoire in a similar convention to abacavir, while
those with no T-cell liability did not (180). This concept was
further explored via the use of the b-lactam antibiotic
flucloxacillin which was identified to covalently haptenate
HLA-B*57:01 native peptides which were subsequently
processed and presented on the MHC for T-cell recognition.
This occurred through multiple mechanisms, namely, through
antigen processing and direct haptenation of pre-presented
peptides. Indeed, utilization of m/s analysis identified the
presence HLA-B*57:01 peptides that were covalently modified
with flucloxacillin haptens at lysine and arginine (181).
An obvious drawback of the peptide elution studies is the
extent of technical demand; up to 1x109 cells can be required for
the incubation in the presence of the drug prior to conducting
the elutions, mandating laborious cell culture. In the cases where
specific HLA alleles are implicated, transfection of B-cell lines
with the relevant alleles is standard procedure, further
complicating matters, though a number of such cell lines
expressing HLA alleles of interest are now commercially
available. There are also procedural challenges pertaining to
the translational relevance of peptides that arise through
elution of transformed cell lines subject to extended culture,
from which peptides are eluted in a process that may not entirely
recapitulate peptides actually presented. Of considerable concern
on these lines is the reported yield of peptides from such
procedures (182). Further issues lie with the analysis softwares
used for immunoproteomic profiling, as they exhibit
shortcomings in terms of detection, particularly of drug-
adducted peptides; expert mass spectrometric/adductomic
analysis is therefore necessitated in many studies. Thus, the
considerable technical demands, translational limitations and
the level of expertise required to process analytical findings
have largely confined such methods to specialist investigative
studies. Peptide elution studies are therefore at the time of
writing very low throughput, expensive assays which are
geared toward identification of critical neoantigens (eluted
peptides), and thereby the nature of culprit HLA presented T-
cell epitopes associated with treatment of APCs, affording
valuable insight into the mechanisms of T-cell activation by a
given compound. Encouragingly, peptide elution methods
feature with increasing frequency in various oncological
applications such as peptide vaccination and adoptive cell
transfer workflows where the field is now entering a realm of
discovery in personalised/tumour personalised therapeutic
approaches (183–185).Frontiers in Immunology | www.frontiersin.org 16Covalent Binding Studies
Considered as the “gold standard” and often featuring as a
synergistic counterpart to trapping assays are covalent binding
studies. Here, radiolabelled analogs of the candidate compound
are synthesised to facilitate the measurement of covalent binding
in various models. Such studies commonly feature in-vitro
studies on human and rat liver preparations (microsomes,
hepatocytes), to investigate covalent binding and interspecies
translatability (154). As well as in-vivo models where rodent
species are subject to either quantitative whole body
autoradiography or radiometric analysis of harvested tissues
(coupled with excretion studies) in order to determine
disposition of drug-related material (186). These studies are
informative in terms of qualitatively and quantitatively
scrutinizing covalent binding, thereby offering insight into the
extent of and localisation of hapten formation and thus which
organs may be most likely targeted. However, information
derived from such studies comes with several notable caveats.
Firstly, custom radio-synthesis of a compound requires careful
selection of radioactive atom placement to avoid metabolism
induced loss, and so is an expensive pursuit, not well suited to
high throughput screening. Secondly, the limitations of
translational relevance of human based in-vitro assays as well
as utility of rodents within in-vivo studies must always be
considered. Thirdly, as with failings of electrophilic trapping
and adductomics, studies of this type will not be effective in
detecting compounds which confer antigenicity through non-
covalent mechanisms.
Finally, there is much ambiguity as to the advisable course of
action to take upon the discovery of covalent binding, with
multiple confounding factors such as the lack of definitive and
transparently quantifiable translation to toxicity decisions (187),
with projected drug dose, purpose, and mechanism of action
complicating the implementation of an isolated, binary decision.
These assays are therefore to be interpreted in the context of a
weight of knowledge accrued on a given chemical entity, to
inform decision making in drug design, and ultimately serve to
help direct drug design toward a lead optimization process that
mitigates/minimalizes bio-activation.
Enzyme Inactivation
Another avenue by which toxicity can be identified is through
detection of mechanism-based inhibition of metabolic enzymes
(mainly CYPs) (188). Various applications of this principle and
the relevant models are described adeptly in (186). Although not
proving the formation of reactive metabolites per-se, findings of
enzyme inactivation are often indicative that compounds
undergo bioactivation. In terms of liabilities for the culprit
compound, enzyme inhibition may result from the alkylation
of the enzyme (often by the reactive metabolite the enzyme
catalyses the formation of), which may provoke an immunogenic
response through neoantigen generation such as that seen with
halothane (189) and tienilic acid (190). An important
consideration with this type of assay is that it is already
integrated into drug development, and may therefore shed
light on potential sources of neoantigens responsible forApril 2021 | Volume 12 | Article 630530
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idiosyncratic liver injury) and highlight the responsible enzyme
for reactive metabolite formation and antigenic generation early
in preclinical development.
Antigen Presenting Cell Maturation/
Activation Assays
While the antigenicity of a compound is important in terms of
density/affinity/variety of antigens produced, another important
component of drugs liabilities for hypersensitivity reactions may
well be its capacity to generate signal 2. Indeed, classic studies
have elegantly demonstrated a distinction and synergy between a
chemical sensitizer and an irritant (191–193), thus, a
compound’s intrinsic capacity to elicit both signal 1 and 2
contributes to its overall sensitization potential. One can
consider this phenomenon in a manner akin to vaccines; while
peptide epitopes are the focal point of the resulting T-cell
response, co-administered adjuvants are often required to
provoke immune elicitation rather than tolerance to the
objective epitope.
This theme is evident within T-cell priming assays to
compounds, where maturation stimuli cocktails such as LPS/
TNF-a are deployed in order to mature dendritic cells prior to
co-culture and facilitate T-cell priming (194, 195). From this
foundation a conclusion can be drawn that a compound that
possesses both qualities is less desirable than either in isolation,
as such a compound is self-propagating in terms of T-cell
liabilities. Certainly, assays that concentrate on a compounds
capacity to promote APC maturation have proven effective in the
realm of contact sensitization, with the human cell line activation
test (h-CLAT) a validated and widely accepted assay routinely
used for determination of sensitizer potential of prospective
compounds (196–199). Intriguingly, such assays can actually
distinguish between irritants and sensitizers (200). Some drugs
containing structural alerts can indeed elicit direct semi-
maturation of dendritic cells directly, as has been demonstrated
within h-CLAT assays (196, 201) and in monocyte derived
dendritic cells (64) for penicillin G and amoxicillin respectively.
However, this rather appeasing correlation is afflicted with the
same limitations as structural alerts, in that bioactivation can also
generate chemical species capable of APC maturation as seen with
nitrososulfamethoxazole (202) thus limiting application of such
assays unless competent metabolizing systems are in place.
Additional consideration can be given to the contiguity between
danger signaling a drug may elicit through direct toxicological
mechanisms, and the bearing that this may have on the
interpretation of antigens and target tissue for adaptive immune
sequelae. Indeed, within contact sensitization studies, response
element reporters are used to detect cellular stress in assays such as
keratinoSens™ (203), and combinatorial models including these
types of assays are being pursued with increasing frequency (204,
205). Comparable response element/gene expression based assays
have also been evaluated within hepatic models with some merit
(206, 207). Investigation of the hepatic-innate immune interface
for liver injury causing drugs in the form of supernatant/
exosomal transfer experiments has yielded meagre returns toFrontiers in Immunology | www.frontiersin.org 17date with no overt increase in maturation marker expression of
dendritic cells observed, although release of various cytokines
was reported (208, 209), as was the basis for a communication
pathway between hepatocytes and the innate immune system
(210–214). These experimental platforms have paved the way for
development of a new series of co-culture models that explore
this interface in a fashion that may be amenable to medium
throughput screening (215), offering a promising avenue for
APC activation based assays to be implemented alongside
conventional direct toxicological studies. Ultimately, there does
appear to be potential utility for assays that focus on the intrinsic
potential for a compound to generate signal 2, and they have
proven useful in contact sensitizer classification. However,
compounds that cause drug hypersensitivity that do act
through such mechanisms appear to do so subtly, thus, current
models are of inadequate sensitivity to draw robust verdicts on a
compounds liability to cause hypersensitivity. In any case, for
these adjuvant/perception type assays to be interpreted
effectively they will likely need to be paired with one or more
assays that indicate a compounds capacity to generate signal 1. It
also needs to be accepted that with hypersensitivity reactions
often occurring at extremely low frequencies, coincidental
events that provide danger signaling; infections/trauma/co-
medications/environmental factors and perception of cross-
reactive antigens may play a role in at least some individuals
and therefore serve to reduce or even nullify the necessity for
a compound to generate an adjuvant signal in order to elicit
T-cell responses.
In-Vitro Priming Assays
Competent in-vitro assessment of the potential of small
molecular weight compounds to elicit de-novo T-cell responses
has been an aspiration within the field of hypersensitivity for
some time, with establishment and validation of such screening
assays currently an unmet need in drug development
programmes. Early studies to this end consisted of a simple
repetitive stimulation of drug-naïve donor PBMC with drug and
a 48hr stimulation culture followed by a 16hr 3H-thymidine
incorporation period conducted under IL-2 deprived conditions
(216). In recent times, efforts have been made to adapt
established peptide priming methods (194, 217) into a
formulation which facilitates the incorporation of drug-related
antigens (195). These assays, repurposed from their original
application in the field of contact sensitization (218), entail the
co-culture of cytokine-induced dendritic cells derived from
monocytes (6 day culture, matured overnight with LPS/TNF-a)
with the naïve T-cell component of PBMC in the presence of
antigen for 8-14 days, followed by a re-constitution and re-
challenge with a fresh batch of dendritic cells and drug antigen
(195). Such procedures have been utilized in the exploration of de-
novo priming to numerous compounds, with varying degrees of
priming observed, and encouragingly, some dependency on the
expression of HLA risk allele for selected drugs (219, 220).
Additionally, the priming assay is sensitive to perturbation of
immune-regulation, with the integration of immune checkpoint
inhibitors influencing the intensity of priming to compounds (221,April 2021 | Volume 12 | Article 630530
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16, 18).
Unfortunately, while the in-vitro priming assays consistently
yield robust priming responses to the paradigm compound
nitrososulfamethoxazole and contact sensitizers such as
bandrowski’s base, there are instances (as for the parent drug
sulfamethoxazole) where they do not even appear as adept as the
previously described PBMC methods at detecting drug-specific
responses (216, 223). This has been attributed to a lack of
sensitivity as signals from T-cells present at low precursor
frequencies are lost among the “noise” generated by the bulk
T-cell lines produced through T-cell priming assays, as has been
demonstrated by limiting dilution and clonal characterization
studies (223). Recently, this lack of sensitivity has been addressed
through an additional iteration of the priming assay (224), which
has resulted in experimental procedures closely aligned with
those described for contact sensitization (225), which permits
greater numbers of experimental replicates comprised of
miniaturized priming cultures. This has facilitated detection of
drug-specific responses arising from rare T-cells, albeit at the
price of more turbulent baselines relative to the conventional
priming assay. Immuno-regulatory aspects of the T-cell multi-
well assay (TMWA) have also been evaluated, with evidence
for modulation of priming to compounds by checkpoint
inhibitors (224).
It is fair to consider T-cell priming assays of each format as in-
development. Several limitations of these assays encumber their
implementation as potential screening assays within the drug
development process. The first is their sensitivity; although the
TMWA represents progress in this avenue, it is still limited with
many pharmaceuticals, especially compounds that do not
categorise as contact sensitizers. Another limitation is that of
inputting the “correct”, or rather the most immunologically
relevant derivative of the drug; as with the diagnostic assays, these
assays are comprised of metabolically incompetent cell types
(dendritic cells and T-cells). Thus, if a metabolite’s formation is
dependent on metabolically active cell types is responsible for a
drug’s immunological liabilities, as is the case for many
pharmaceuticals, then it is unlikely that T-cell priming assays in
their current format will adequately detect immunogenicity from
the input of parent drug. The detection of such responses therefore
depends on; 1. The integration of a translationally relevant
metabolizing system into such assays, or 2. The identification of
metabolites, their synthesis and input into assays. The former of
which is impeded by allogenicity/cumbersome nature of such
systems, and the latter represents a challenging, expensive and
possibly impractical prospect, especially regarding extensively
metabolized compounds. Other limitations include the cellular
input (PBMCs) as tissue resident T-cells are neglected (as with
diagnostic assays), poor representation of certain T-cell responses
(e.g., CD4 may predominate), and the possibility of biased effector
phenotypes driven by the maturation stimuli utilized.
The weight of risk determinant that HLA allele expression
contributes to T-cell responses involved in hypersensitivity is
highly variable; with some drugs exhibiting extreme odds ratios
to particular alleles (HLA-B*5701 and abacavir) (42) while othersFrontiers in Immunology | www.frontiersin.org 18have no known associated HLA. An important question is
whether the former represent an intractable issue when it
comes to preclinical screening; the incorporation of HLA allele
variants into such assays would mandate dozens of parallel
assays, even to cover the most abundant alleles. Finally, the
question of whether these de-novo responses actually do translate
well to what is seen within patients is poorly defined. Within
priming cultures, regulatory (amongst other) constituents of
PBMC are removed and extreme inflammatory conditions are
used in order to provoke T-cell responses against compounds.
Indeed, the question answered from a positive assay result will
almost certainly be “can” rather than “would” T-cells be activated
by a given compound. Regardless, satisfactory development of T-
cell priming assays would likely be a welcome addition to the
barrage of available immunotoxicological assays.
In-Silico Approaches
The recent emergence of nascent in-silico modelling systems in
toxicological prediction of compounds hopefully portends a new
era in the field of prediction of idiosyncratic adverse drug
reactions. Systems currently available include aforementioned
structural alert/chemical characteristic based softwares (109,
226–228), and models that attempt to integrate in-vitro
findings to a toxicity assessment output (229, 230). DILIsym is
perhaps the most prominent of these in-silico biological systems
(231) and though it currently lacks an adaptive immune
component, it has still exhibited utility when investigating/
comparing compounds which appear to proceed through
adaptive mechanisms (232–234), perhaps due to factors that
propagate deployment of such abberant immunological
responses. With such powerful in-silico methods at the disposal
of the field, there are examples where modelling has been utilised
even with the more complex assays such as immunopetidomics,
with docking models for HLA based risk assessment of
prospective compounds a particularly ambitious venture of
interest (235). However, a caveat of currently employed
docking studies is that they focus on only one component of
the immunological synapse; the HLA, and therefore do not
reflect interactions dependent on other interchangable
components. Exceptionally challenging barriers exist to hinder
the successful, universal, transition to prediction of signal 1 for a
given compound within in-silico docking models through
modelling of the focal point of the immunological synapse.
The first is the profound polymorphism of HLA itself; to the
extent that, coupled with heterozygosity of individuals, HLA
genotyping can be utilized for paternal testing (236) and forensic
science (237). The allelic variation is mostly restricted to residues
that form the peptide binding groove, with important
consequences for the respective peptide binding repertoire of
each HLA (238). Second is the peptide repertoire that is
expressed, which is diverse and will exhibit cell type and status
specific profiles (239–241). Third is the vast heterogeneity of T-
cell receptors, with clonotypic expression of TCRs shown to be
important for hypersensitivity reactions occurring with a select
number of drugs in the context of risk HLAs (242, 243). TCRs
possess remarkable variation including that of hypervariableApril 2021 | Volume 12 | Article 630530
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topology with the HLA-peptide ligand (245).
Upon successful modeling of those components, topological
perturbations induced by drug and any relevant metabolites, via
each of the known mechanisms by which small molecular weight
compounds activate T-cells would need to be investigated;
hapten (conjugated peptides presented), Pi (pharmacological
interaction with both TCR and MHC-peptides) and altered
self-repertoire (topological disruption of the HLA-peptide
interaction resulting in alternative TCR specificity). Thus,
while the modification of abacavir (as described in Structural
Alerts) serves as a striking application for in-silico modelling, the
importance of accompanying functional studies was
demonstrated, and the challenges associated with redesign for
circumvention of deleterious interaction with even a single HLA
allele illustrates the scale of development required for these
assays to come to fruition. Moreover, there is no assurance in
such studies that the redesign of immunocophore implicated in
HLA-B*57:01 associated hypersensitivity does not give rise to a
problematic, potentially worse scenario with another HLA allele.
In the future, computer systems may be developed that
incorporate outputs from many of the aforementioned in-vitro
assays to yield an estimated risk assessment based on compound
performance across the board. It must be noted however, that as
discussed, in-silico models will likely only be as good as the data
provided to them. Hence, further development of existing, and
inception of novel assays will likely prove imperative to optimal
implementation of such systems.
Perspective of Preclinical Assays
Great strides have beenmade in the last 50 years to utilise empirical
evidence relating chemical structure to direct and immuno-
toxicological profiles, and to use this alongside preclinical
screening assays in weight of evidence decision making processes.
Despite this, the process is far from perfect, and several high profile
therapeuticshave failedat late stagesofdevelopment in recentyears.
The current approach in industrial drug development heavily relies
on chemical properties, particularly reactivity. This has
substantially contributed to better informed drug design and
more effective management of the risk profiles of established
compounds with hypersensitivity liabilities. However, as outlined
herein, these characteristics do not directly or completely translate
tobiological response, andmuchof the focushas beenonmitigating
direct toxicological properties rather than immunological liabilities
per-se, and so there is an unmet requirement for cell-based assays to
indicate these potential risks of compounds. The unfortunate truth
in the arena of preclinical assays for hypersensitivity (delayed-type
hypersensitivity reactions in particular) is that there is not yet an
assay with adequate predictive capacity to mitigate such risk. As
such, S8 2.7 of the ICH safety guidelines offers little in terms of
recommended precautionary action (246). No in-vitro preclinical
assay exists which possesses overarching applicability across all
immune-mediated hypersensitivity reactions, which perhaps
reflects the heterogeneity of such reactions. A quixotic,
overarching model is unachievable at this time and so a
composite of existing and future assays that feed into the two
signalmodel is likely tobe key to improvement and further bridgingFrontiers in Immunology | www.frontiersin.org 19of the gap in-vitro.As outlined in (Figure 2), there are a plethora of
factors that feed into both of these attributes, while drug
development workflows can focus on drug-dependent liabilities,
many of these factors are drug-independent. Careful due diligence
in the form of target safety assessments may shed light on potential
challenges with intended populations and pharmacological effects,
and help aid with construction of product-tailoredmodels. In-silico
methodsmay also be useful in this regard to incorporate population
specific parameters for initiating toxicologicalmechanisms andalso
to facilitate safety margin approximations. However, it will
ultimately be incredibly difficult to build idiosyncratic features
into preclinical development models, and so we may need to
accept there will always be unknowns in this regard with each
development venture. This is where precision medicine is needed,
and HLA genotyping has proven how mechanistic insight and
astute pharmacovigilance can be critical (to the point of therapeutic
resurrection) once a drug encounters such issues within the clinic.CONCLUSIONS
The prediction of hypersensitivity/idiosyncratic liabilities for a
given compound in drug development and diagnosis of
individuals with such ailments remain largely intractable issues.
Investment required for development of new therapeutics is
ascending, thus so too is the cost of attrition due to
hypersensitivity. Moreover, in this era of immunological
enlightenment, where pharmacological attempts to wield the
immune system are becoming ever more frequent, it is becoming
apparent that these therapeutics and their associated riskswill bring
thefield to the fore of development toxicology. Better in-vitro assays
to diagnose and predict immune liabilities of therapeutics are
therefore long awaited and needed more now than ever. Half a
century of investment and progress in understanding the
mechanistic aspects of these reactions has yielded some great
returns. As our understanding of hypersensitivity reactions
continues to evolve, so too will our progression in modelling,
accurate diagnosis and prediction of them in the coming decades.
One anticipates that key frontiers in the immediate futurewill be the
modernisation andharmonisation of in-vitrodiagnostic assays, and
the investment in (and composite interpretation of) biological
assays that independently encapsulate antigenicity or
adjuvanticity of therapeutics.AUTHOR CONTRIBUTIONS
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RM, et al. Recognition of iodixanol by dendritic cells increases the cellular
response in delayed allergic reactions to contrast media. Clin Exp Allergy
(2011) 41(5):657–64. doi: 10.1111/j.1365-2222.2010.03693.xFrontiers in Immunology | www.frontiersin.org 2161. Whitaker P, Meng X, Lavergne SN, El-Ghaiesh S, Monshi M,
Earnshaw C, et al. Mass Spectrometric Characterization of Circulating
and Functional Antigens Derived from Piperacillin in Patients with
Cystic Fibrosis. J Immunol (2011) 187(1):200–11. doi: 10.4049/
jimmunol.1100647
62. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of
drug hypersensitivity. Allergy (2004) 59(8):809–20. doi: 10.1111/j.1398-
9995.2004.00547.x
63. Walker C, Kristensen F, Bettens F. Lymphokine regulation of activated (G1)
lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2
production. J Immunol (1983) 130(4):1770–3.
64. Rodriguez-Pena R, Lopez S, Mayorga C, Antunez C, Fernandez TD, Torres
MJ, et al. Potential involvement of dendritic cells in delayed-type
hypersensitivity reactions to b-lactams. J Allergy Clin Immunol (2006) 118
(4):949–56. doi: 10.1016/j.jaci.2006.07.013
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